Rosemary A Crane
CIK 1443343 · CEO and President · last filed 2026-06-08
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$5.15M
Companies
9
Total Filings
47
Lifetime Open-Market Net
$16.0K
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| TEVA | Director | 127,739 | $35.04 | $4.48M | -$34.0K | 19 | 2026-06-08 |
| CERT | Director | 45,672 | $7.78 | $355.3K | $0 | 5 | 2026-05-15 |
| TARS | Director | 5,350 | $58.98 | $315.5K | $0 | 6 | 2024-06-25 |
| Catalent, Inc. (CTLT) Delisted | Director | 23,873 | $63.48 | $1.52M | $0 | 7 | 2023-10-31 |
| PDSB | Director | 10,000 | $0.69 | $6.9K | $0 | 1 | 2019-03-18 |
| EDGE | Director | — | $49.66 | — | $0 | 3 | 2018-08-15 |
| STRATA Skin Sciences, Inc. (MELA) Delisted | CEO and President | 67,570 | — | — | $50.0K | 2 | 2014-02-06 |
| EPOCRATES INC (EPOC) Delisted | President & CEO | — | — | — | $0 | 1 | 2011-03-28 |
| Targanta Therapeutics Corp. (TARG) Delisted | Director | — | — | — | $0 | 1 | 2008-08-26 |
Recent Filings · Page 5 of 5
47 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2018-06-20 | EDGE | Grant (A) | — | $0 | EDGAR |
| 2018-06-07 | TEVA | Grant (A) | — | $0 | EDGAR |
| 2017-09-20 | EDGE | Grant (A) | — | $0 | EDGAR |
| 2014-02-06 | STRATA Skin Sciences, Inc. (MELA) Delisted | Buy (P) | +67,570 | $50.0K | EDGAR |
| 2013-11-13 | STRATA Skin Sciences, Inc. (MELA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2011-03-28 | EPOCRATES INC (EPOC) Delisted | Grant (A) | — | $0 | EDGAR |
| 2008-08-26 | Targanta Therapeutics Corp. (TARG) Delisted | Grant (A) | — | $0 | EDGAR |
Showing 41–47 of 47
Prev
Page 5 of 5
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.